Ruben A. Mesa, MD, FACP:When determining treatment for patients with myelofibrosis, I am mindful of 2 things: First, the patient’s prognosis. Are they low, intermediate, or at higher risk, depending upon whatever score you choose to use. The majority of patients are intermediate to high risk. The minority presenting with a lower-risk profile, particularly if we are quite studious in terms of trying to find those risk factorsit’s only a minority, perhaps 20% or less who really are low risk. So the majority are intermediate or high risk.
Secondly, I look to see what the burden of disease that they’re facing is. Is there anemia? Are there symptoms? Is there enlargement of the spleen? Is there movement toward acute leukemia, or is there progression? I say this because the 2 issues are complementary. The decision-making first begins with: Should a patient proceed toward a stem cell transplant in the near future or not? I believe that is a consideration according to our current guidelines for patients with intermediate- and high-risk disease, particularly if they’re younger.
There are many variables that factor into that decision for having a stem cell transplant. Is there a donor? What is the exact prognostic risk for the patient? What is the patient’s age? What is the patient’s desire toward going to a stem cell transplant? It is one of the most complex medical therapies we have. It carries with it significant risk. Anyone who says that is an easy decision for a patient is clearly not the individual facing the decision. It’s a very complex part.
So first I make that decision with the patient. Transplant in the near future? Transplant in the distant future? Or, likely, no transplant at all? Then we evolve into the discussion of medical therapy. Medical therapy has the potential to benefit the majority of patients with myelofibrosis. According to our current NCCN [National Comprehensive Cancer Network] guidelines, for asymptomatic, low-risk patients we may choose to observe them or place them on a clinical trial. But for individuals who are low risk and symptomatic, intermediate-1 or higher risk, we will at least consider medical therapy, potentially with ruxolitinib.
The patient we are discussing is 72 years of age and has intermediate-2 risk disease. So the question arises: Should we consider a stem cell transplant for this patient?
It would be a discussion. It would be accurate to say that the minority of 72-year-old patients who would like to proceed with a stem cell transplant have an appropriate donor and are felt to, overall, be good candidates for stem cell transplantation. In the majority of such individuals, we likely would go with medical therapy. But as with all things, there are exceptions, depending upon the physiologic health of the patient, how aggressive they really wish to be in terms of their healthcare, and clearly, the resources available to them.
Transcript edited for clarity.
Case: 72-Year-Old Man Diagnosed With Primary Myelofibrosis
December 2018
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More